8-KEarnings & ResultsExhibits & Filings

JOHNSON & JOHNSON 8-K Report, Financial Results (Oct 19, 2010)

Filed October 19, 2010For Securities:JNJ

Summary

Johnson & Johnson (JNJ) filed an 8-K on October 19, 2010, to report its third-quarter results for the period ended October 3, 2010. The filing includes a press release and supplementary sales data. While the 8-K itself does not contain the detailed financial figures, it serves as the official notification that these results have been publicly released, allowing investors to access the press release and accompanying financial statements for a comprehensive understanding of the company's performance during the quarter. Investors should refer to the attached exhibits, specifically the press release (Exhibit 99.15) and the unaudited condensed consolidated statement of earnings and sales data (Exhibit 99.20), to analyze key metrics such as revenue growth, earnings per share (EPS), and segment performance. This information is crucial for assessing JNJ's operational execution, profitability, and overall financial health in the third quarter of 2010, and for making informed investment decisions.

Key Highlights

  • 1JNJ filed an 8-K on October 19, 2010, announcing its third-quarter 2010 financial results.
  • 2The report covers the third quarter ended October 3, 2010.
  • 3Key information is provided via an attached press release (Exhibit 99.15).
  • 4Unaudited supplementary sales data and condensed consolidated statement of earnings are also included as an exhibit (Exhibit 99.20).
  • 5Investors are directed to these exhibits for detailed financial performance analysis.
  • 6The filing serves as official notification of the Q3 2010 earnings release.

Frequently Asked Questions

The primary purpose of this 8-K filing is to officially announce Johnson & Johnson's financial results for the third quarter of 2010, which ended on October 3, 2010. It directs investors to the accompanying press release and financial statements for the detailed performance data.

The specific financial results, including sales and earnings, can be found in the exhibits attached to this 8-K filing. Specifically, refer to Exhibit 99.15 (Press Release) and Exhibit 99.20 (Unaudited Comparative Supplementary Sales Data and Condensed Consolidated Statement of Earnings).

Investors should look for key financial metrics such as total sales, sales by segment (e.g., Pharmaceuticals, Medical Devices, Consumer Health), net earnings, earnings per share (EPS), and any guidance provided by the company. Analyzing these will help understand the company's performance and profitability during the third quarter of 2010.